Key result
Volume removal via a single hemodialysis session had no significant impact on elevated NT-proBNP levels in patients with end-stage kidney disease or acute kidney injury presenting with hypervolemia.
Why the study?
Although measuring pre- and post-hemodialysis NT-proBNP is common in patients hospitalized with volume expansion, the clinical value of repeated measurements and the effect of volume removal on levels remained unclear.
Does volume removal via a single hemodialysis session reduce elevated NT-proBNP levels in patients with ESKD or AKI presenting with hypervolemia?
Observational (n=41)
Yes
Does volume removal via a single hemodialysis session reduce elevated NT-proBNP levels in patients with ESKD or AKI presenting with hypervolemia?
A single hemodialysis session does not significantly reduce elevated NT-proBNP levels in hypervolemic patients with ESKD or AKI, indicating that routine post-dialysis NT-proBNP measurement lacks clinical utility.
Answers are grounded in this paper and cite their sources.
Post-dialysis NT-proBNP reassessment may not reflect volume removal; leaves open its role in serial monitoring or guiding ultrafiltration.
INTRODUCTION AND AIM: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) is highly sensitive and specific for the diagnosis of congestive heart failure (CHF). Most patients with end-stage kidney disease (ESKD) on renal replacement therapy have an elevated NT-proBNP plasma level due to volume gain between dialysis sessions. Measuring plasma NT-proBNP levels before and after hemodialysis (HD) in patients hospitalized with volume expansion is a common practice. This study aimed to determine the clinical value of repeated plasma NT-proBNP measurements in patients with ESKD or acute kidney injury (AKI) requiring HD and to study the effect of volume removal via HD on NT-proBNP plasma levels. METHODS: We conducted a retrospective analysis of patients admitted to two community hospitals over a three-year period (from January 1, 2020, to December 31, 2022). Patients with AKI requiring HD or ESKD were screened if they had an admission diagnosis of volume expansion including acute CHF or pulmonary edema that was verified radiographically and by physical examination. Patients who had a plasma NT-proBNP level measured at admission and a repeat measurement 2-12 hours after HD were included in this study. Over the three-year period, 36 patients with ESKD and five patients with AKI requiring HD fulfilled the inclusion criteria. RESULTS: Volume removal via HD had no impact on NT-proBNP levels in ESKD or AKI patients (ESKD p=0.7858 and AKI p=0.6903). Our patients exhibited markedly elevated NT-proBNP due to volume expansion and renal dysfunction. During the study period, 30% of the patients with ESKD (11/36) died. CONCLUSION: Volume expansion is the main factor causing elevated NT-proBNP levels in acute or chronic HD patients. Reducing predialysis volume expansion with a single hemodialysis session has no impact on NT-proBNP level. Therefore, repeating the NT-proBNP level post-HD has no clinical value. Our data suggest that NT-proBNP is a useful cardiac biomarker for volume expansion, and its elevated level predicts high cardiovascular mortality and recurrent hospitalizations in acute and chronic HD patients.
No takes yet. Share an insight, caveat, or question.
Tinawi et al. (2025) conducted an observational in Hypervolemia in ESKD or AKI requiring hemodialysis (n=41). Volume removal by hemodialysis vs. Pre-hemodialysis baseline was evaluated on NT-proBNP level post-hemodialysis (pg/mL) (p=0.9110). Volume removal via a single hemodialysis session had no significant impact on elevated NT-proBNP levels in patients with end-stage kidney disease or acute kidney injury presenting with hypervolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: